Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894425 | 1.00 | MEN1 (0.42) | MEN1KMT2ASIRT6MAPTPOLB | |
| SCHEMBL2393061 | 0.84 | PIK3CD (0.50) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL9145647 | 0.81 | SIRT6 (0.46) | MEN1KMT2ASIRT6MAPTPOLB | |
| SCHEMBL9145657 | 0.81 | SIRT6 (0.46) | MEN1KMT2ASIRT6MAPTPOLB | |
| SCHEMBL2720160 | 0.81 | SIRT6 (0.46) | MEN1KMT2ASIRT6MAPTPOLB | |
| SCHEMBL10510829 | 0.78 | POLB (0.47) | MEN1KMT2ASIRT6MAPTPOLB | |
| SCHEMBL1892540 | 0.78 | MAP3K12 (0.42) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL1896831 | 0.78 | MAP3K12 (0.42) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL1898615 | 0.78 | MAP3K12 (0.42) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL2392194 | 0.78 | SIRT6 (0.40) | MEN1KMT2ASIRT6MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| WO-2011054922-A1 | SALTS OF FUSED PYRAZINE COMPOUNDS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2011-05-12 | — | — | WO | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009135885-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, NLRP3 | MEN1 3936/4885KMT2A 4441/4885SIRT6 1245/4885 |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | MEN1 4306/4885KMT2A 4452/4885SIRT6 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.